Last update March 24, 2019
We do not have alternatives for Fluorouracil (Topical use).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Fluorouracil (Topical use) belongs to this group or family:
Main tradenames from several countries containing Fluorouracil (Topical use) in its composition:
|Oral Bioavail.||6 - 10 (Dermat.)||%|
|Protein Binding||10 (8 - 12)||%|
|T½||0.27 (0.13 - 0.34)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Fluorouracil is an analogue of uracil which acts as an antimetabolite and is used as a cream or solution in the local treatment of precancerous and cancerous skin lesions.
It is also administered intravenously for other types of cancer. It is excreted in breastmilk in undetectable, clinically insignificant amounts (Peccatori 2012) that can be explained by its pharmacokinetics: rapid degradation to non-active metabolites and very low liposolubility (Pistilli 2013).
Because absorption through the skin is minimal, the topical application of fluorouracil over a small body surface does not pose any risk to the infant, therefore it is not necessary to interrupt breastfeeding (Hale 2017 p388).
It is advisable to avoid application in places that may come into direct contact with the infant, or clean well before the infant can come into contact with the treated area of the mother’s skin.
Given the strong existing evidence on the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, advising each mother who wishes to continue with breastfeeding on an individual basis (Koren 2013).
See below the information of this related product: